PURPOSE: We identified factors at diagnosis that are significantly associated with time to prostate cancer specific mortality following radical prostatectomy or external beam radiation therapy. MATERIALS AND METHODS: The study cohort included 1,453 men treated with radical prostatectomy (1,095) or external beam radiation therapy (358) for localized prostate cancer between 1989 and 2002. Cox regression multivariate analysis was used to evaluate whether prostate specific antigen, prostate specific antigen velocity, biopsy Gleason score and clinical tumor category at diagnosis were significantly associated with time to prostate cancer specific mortality following radical prostatectomy or external beam radiation therapy. RESULTS: In addition to increasing prostate specific antigen (p < or =0.04) and biopsy Gleason score 8 to 10 disease (p < or =0.02), prostate specific antigen velocity more than 2 ng/ml yearly was significantly associated with shorter time to prostate cancer specific mortality in patients treated with radical prostatectomy (adjusted HR 12, 95% CI 3 to 54) and external beam radiation therapy (adjusted HR 12, 95% CI 3 to 54) compared with that in men with prostate specific antigen velocity 2 ng/ml yearly or less (p < or =0.001). Despite low risk disease 7-year estimates of prostate cancer specific mortality were 5% to 19% in patients in whom prostate specific antigen increased by more than 2 ng/ml during the year before diagnosis compared with less than 1% in those with a prostate specific antigen increase of 2 ng/ml or less. CONCLUSIONS: Despite prostate specific antigen level less than 10 ng/ml and Gleason score 6 cancer a prostate specific antigen increase of more than 2 ng/ml during the year before diagnosis places a man at high risk for prostate cancer death following radical prostatectomy or external beam radiation therapy.
PURPOSE: We identified factors at diagnosis that are significantly associated with time to prostate cancer specific mortality following radical prostatectomy or external beam radiation therapy. MATERIALS AND METHODS: The study cohort included 1,453 men treated with radical prostatectomy (1,095) or external beam radiation therapy (358) for localized prostate cancer between 1989 and 2002. Cox regression multivariate analysis was used to evaluate whether prostate specific antigen, prostate specific antigen velocity, biopsy Gleason score and clinical tumor category at diagnosis were significantly associated with time to prostate cancer specific mortality following radical prostatectomy or external beam radiation therapy. RESULTS: In addition to increasing prostate specific antigen (p < or =0.04) and biopsy Gleason score 8 to 10 disease (p < or =0.02), prostate specific antigen velocity more than 2 ng/ml yearly was significantly associated with shorter time to prostate cancer specific mortality in patients treated with radical prostatectomy (adjusted HR 12, 95% CI 3 to 54) and external beam radiation therapy (adjusted HR 12, 95% CI 3 to 54) compared with that in men with prostate specific antigen velocity 2 ng/ml yearly or less (p < or =0.001). Despite low risk disease 7-year estimates of prostate cancer specific mortality were 5% to 19% in patients in whom prostate specific antigen increased by more than 2 ng/ml during the year before diagnosis compared with less than 1% in those with a prostate specific antigen increase of 2 ng/ml or less. CONCLUSIONS: Despite prostate specific antigen level less than 10 ng/ml and Gleason score 6 cancer a prostate specific antigen increase of more than 2 ng/ml during the year before diagnosis places a man at high risk for prostate cancer death following radical prostatectomy or external beam radiation therapy.
Authors: Cara L McDermott; David K Blough; Catherine R Fedorenko; Neeraj K Arora; Steven B Zeliadt; Megan E Fairweather; Ingrid Oakley-Girvan; Stephen K Van Den Eeden; Scott D Ramsey Journal: Support Care Cancer Date: 2010-12-01 Impact factor: 3.603
Authors: Scott D Ramsey; Steven B Zeliadt; David K Blough; Catherine R Fedorenko; Megan E Fairweather; Cara L McDermott; David F Penson; Stephen K Van Den Eeden; Ann S Hamilton; Neeraj K Arora Journal: Urology Date: 2012-05 Impact factor: 2.649
Authors: M Bonet; A Merglen; G Fioretta; E Rapiti; I Neyroud-Caspar; R Zanetti; R Miralbell; C Bouchardy Journal: Clin Transl Oncol Date: 2009-05 Impact factor: 3.405
Authors: Donkena Krishna Vanaja; Mathias Ehrich; Dirk Van den Boom; John C Cheville; R Jeffrey Karnes; Donald J Tindall; Charles R Cantor; Charles Y F Young Journal: Cancer Invest Date: 2009-06 Impact factor: 2.176
Authors: Scott D Ramsey; Steven B Zeliadt; Neeraj K Arora; Arnold L Potosky; David K Blough; Ann S Hamilton; Stephen K Van Den Eeden; Ingrid Oakley-Girvan; David F Penson Journal: Urology Date: 2009-07-09 Impact factor: 2.649
Authors: Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Julia Wade; Sian Noble; Kirsty Garfield; Grace Young; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Jane Blazeby; Richard Bryant; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Alan Paul; Edgar Paez; Philip Powell; Stephen Prescott; Derek Rosario; Edward Rowe; David Neal Journal: Health Technol Assess Date: 2020-08 Impact factor: 4.014
Authors: Naomi L Sharma; Charlie E Massie; Falk Butter; Matthias Mann; Helene Bon; Antonio Ramos-Montoya; Suraj Menon; Rory Stark; Alastair D Lamb; Helen E Scott; Anne Y Warren; David E Neal; Ian G Mills Journal: Nucleic Acids Res Date: 2014-04-21 Impact factor: 16.971